What is Macomics?
Founded in 2019 and based in Edinburgh, United Kingdom, Macomics is at the forefront of developing precision medicines designed to modulate macrophages for cancer treatment. Leveraging the expertise of internationally recognized leaders in macrophage biology from the University of Edinburgh, the company is advancing a diversified portfolio of therapies. These therapies target disease-specific tumor-associated macrophages (TAMs) with the goal of moving them towards clinical application. Macomics' proprietary target discovery platform is built upon a deep understanding of macrophage biology, enabling the identification and validation of novel therapeutic targets.
How much funding has Macomics raised?
Macomics has raised a total of $5.9M across 1 funding round:
Unspecified
$5.9M
Unspecified (2021): $5.9M with participation from Caribou Property Limited, Scottish Enterprise, and Epidarex Capital
Key Investors in Macomics
Scottish Enterprise
Founded in 1991, Scottish Enterprise is headquartered in Glasgow, United Kingdom. They are a national economic development agency and a non-departmental public body of the Scottish Government.
Epidarex Capital
Epidarex is a transatlantic venture capital firm focused on building breakthrough life science companies in emerging hubs. Their portfolio includes innovative biopharmaceutical companies developing precision medicines for various health conditions.
Caribou Property Limited
Undisclosed investor participating in the funding round.
What's next for Macomics?
With the recent major strategic investment and planned Series A financing, Macomics is well-positioned to accelerate the progression of its antibody programs toward clinical trials. The company intends to expand its therapeutic portfolio and further invest in its cutting-edge target discovery technology. This strategic capital allocation signals a strong commitment to advancing its pipeline and solidifying its position as a key player in the precision medicine sector, particularly in oncology.
See full Macomics company page
